Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2017 August;83(8) > Minerva Anestesiologica 2017 August;83(8):790-7



Publication history
Cite this article as


A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,623




Minerva Anestesiologica 2017 August;83(8):790-7

DOI: 10.23736/S0375-9393.16.11580-9


language: English

Neuromuscular effect of dexmedetomidine on sevoflurane: an open-label, dose-escalation clinical trial

Hui-Hua KE 1, Huang-Hui WU 1, Qi ZHU 1, Yan ZHANG 1, Jin-Rong XIAO 2, Xiu-Zhu SU 1, Wan-Jing ZHENG 3, Yu-Ping CAI 2, Xiao-Zhi WU 1, Yu-Tong WANG 4, Guo-Zhong CHEN 1, 2, 3

1 Department of Anesthesiology, Fuzhou General Hospital, Fuzhou, China; 2 Department of Anesthesiology, Fuzhou General Hospital Affiliated to Fujian Medical University, Fuzhou, China; 3 Department of Anesthesiology, Fuzhou General Hospital Affiliated to Anhui Medical University, Hefei, China; 4 Department of Emergency, Xijing Hospital, the Fourth Military Medical University, Xi’an, China


BACKGROUND: Sevoflurane presents reliable central neuromuscular effects. However, little knowledge is available regarding the interaction between sevoflurane and demedetomidine. We evaluated the neuromuscular effect of dexmedetomidine on sevoflurane in patients with normal neuromuscular transmission and calculated the 50% effective concentration (EC50).
METHODS: One-hundred and forty-four ASA grade I~II patients with normal neuromuscular transmission, aged 20~60 years old, undergoing lower limbs surgery were enrolled in this open-label, dose-escalation clinical trial. Patients were randomly assigned into 12 groups. Each patient received intravenous 0, 0.5, or 1.0 μg/kg dexmedetomidine 15 min after inhaling 0.7, 1.0, 1.4, or 2.0 MAC sevoflurane. Neuromuscular monitoring was recorded from the adductor pollicis muscle by using acceleromyography with train-of-four (TOF) stimulation of the ulnar nerve (2 Hz every 20 s). TOF ratio was recorded before inhaling sevoflurane, 15 min after keeping constant at target MAC of sevoflurane, 30 min after receiving target dose of dexmedetomidine, and 15 min after sevoflurane washing out.
RESULTS: Sevoflurane produced a concentration-dependent decrease in TOF ratio. Mean TOF ratio in 0.7, 1.0, 1.4, and 2.0 MAC groups was 97.9%, 94.9%, 84.7%, and 77.2%, respectively. Neuromuscular EC50 of sevoflurane was 1.31 MAC (95% CI: 1.236~1.388 MAC). Intravenous 0.5 and 1.0 μg/kg dexmedetomidine decreased 3.1% (EC50: 1.27 MAC [95% CI: 1.206~1.327 MAC]) and 10.7% (EC50: 1.17 MAC [95% CI: 1.122~1.217 MAC]) of neuromuscular EC50, respectively.
CONCLUSIONS: Sevoflurane has a concentration-dependent central neuromuscular effect in patients with normal neuromuscular transmission. Intravenous dexmedetomidine dose-dependently decreases the neuromuscular EC50 of sevoflurane.

KEY WORDS: Sevoflurane - Dexmedetomidine - Neuromuscular monitoring

top of page

Publication History

Issue published online: July 17, 2017
Article first published online: December 22, 2016
Manuscript accepted: December 17, 2016
Manuscript revised: November 15, 2016
Manuscript received: July 18, 2016

Cite this article as

Ke HH, Wu HH, Zhu Q, Zhang Y, Xiao JR, Su XZ, et al. Neuromuscular effect of dexmedetomidine on sevoflurane: an open-label, dose-escalation clinical trial. Minerva Anestesiol 2017;83:790-7. DOI: 10.23736/S0375-9393.16.11580-9

Corresponding author e-mail